Albert Chan, MD
Interventional Cardiology · Columbia, MONPI 1669598629
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,441 of the $14,577 with a category attached, or 85.3%. It is spread thinly across 42 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations.
Across 421 payments — averaging $34.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Medtronic$2K
- Abiomed$1K
- Janssen Research & Development, LLC$1K
- Amgen$1K
- Novartis$810
- plus $6K from 36 others
Across 14 payments — averaging $5467.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$53K
- Amgen$23K
What the payments were for
- Consulting fees$2192%
- Travel & lodging$1,89313%
- Food & beverage$12,44185%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$913
- AVVIGO Guidance System$470
- ONYX FRONTIER$447
- OPTIMIZER$324
- GENERAL - THERAPIES$260
- GENERAL VASCULAR ACCESS$256
- CoreValve Evolut$169
- XARELTO$148
- Avalus$133
- ELCA$125
- Xience Sierra Coronary Stent System$121
- Inpefa$115
- ReCross$113
- FARXIGA$110
- ASAHI PTCA Guide Wire$110
- TherOx DS2 Console$100
- Catheter$100
- Downstream Cartridge$100
How this compares
$14,577 in reported general payments places this provider in the 60th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $63,280 |
| EntrestoSacubitril/Valsartan | 32 | $41,483 |
| Repatha SureclickEvolocumab | 28 | $28,208 |
| FarxigaDapagliflozin Propanediol | 30 | $27,458 |
| XareltoRivaroxaban | 16 | $15,643 |
| Praluent PenAlirocumab | 13 | $15,273 |
| Ezetimibe | 104 | $1,977 |
| Rosuvastatin Calcium | 113 | $1,487 |
| Atorvastatin Calcium | 153 | $1,321 |
| Metoprolol Succinate | 83 | $972 |
| Carvedilol | 97 | $774 |
| Amlodipine Besylate | 119 | $595 |
| Spironolactone | 77 | $560 |
| Losartan Potassium | 54 | $504 |
| Potassium Chloride | 25 | $491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $88 | $63,28046 claims |
| NovartisEntresto | $810 | $41,48332 claims |
| AstraZenecaFarxiga | $583 | $27,45830 claims |
| Johnson & JohnsonXarelto | $452 | $15,64316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Columbia
- Taishi HiraiColumbia$150K
- Arun KumarColumbia$17K
- Michael BrownColumbia$17K
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Gerald MancusoKansas City$402K
- James GranthamKansas City$357K
- Matthew BunteKansas City$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.